Pralsetinib

• CAT Number: I020039
• CAS Number: 2097132-94-8
• Molecular Formula: C₂₇H₃₂FN₉O₂
• Molecular Weight: 533.60
• Purity: 98%
• Target: RET
• Target Protein: P07949
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: IC50: 0.4 nM (Wild type RET), 0.3 nM (RET V804L), 0.4 nM (RET V804M), 0.4 nM (RET M918T), 0.4 nM (CCDC6-RET)
• IUPAC Name: N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
• InChI: InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1
• InChIKey: GBLBJPZSROAGMF-SIYOEGHHSA-N
• SMILES: CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC

Pralsetinib（Cat No.:I020039）is a targeted RET inhibitor used to treat cancers driven by RET gene fusions or mutations, including non-small cell lung cancer (NSCLC), medullary thyroid cancer, and other solid tumors. By selectively inhibiting RET kinase, Pralsetinib blocks the abnormal signaling pathways that promote cancer cell growth and proliferation. Its high specificity reduces off-target effects and improves safety. Pralsetinib has demonstrated significant clinical efficacy in patients with RET-altered cancers, especially those resistant to other treatments, providing a potent and personalized therapy option for managing advanced RET-driven tumors.

Reference

[1]. Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338.